OptiBiotix Health PLC (AIM:OPTI) said a new consumer study supports a recent human trial study to show that its CholBiome products are effective in reducing cholesterol, with 96% of consumers taking CholBiomeX3 reporting a reduction in their total cholesterol levels.
The consumer study was carried out by OptiBiotix subsidiary ProBiotix Health. CholBiomeX3 and CholBiomeBP are ProBiotix's patented and proprietary formulations developed to reduce cardiovascular disease risk using the probiotic strain LPLDL.
In the study, 17% of consumers taking CholBiomeX3 reported a reduction greater than 30% in total cholesterol levels, while 50% of participants reported reductions between 16%-30% and 29% reported reductions between 1%-15%.
Some 88% of consumers said their LDL-cholesterol (so-called "bad" cholesterol) had been reduced.
Among users who took CholBiomeX3 for more than a year, 93% reported reduced levels of both total and LDL-cholesterol.
No consumers reported any side effects from taking the product.
The results build upon another consumer study of CholBiomeX3 carried out in December 2019 in which 95% of users stated that the product was effective.
It follows a recent human clinical study, published on 18 January 2022, which showed a statistical significant effect of LPLDL in reducing total cholesterol, LDL-cholesterol and APO-B.
READ: OptiBiotix Health says latest study supports case for LPLDL as an alternative to statins
"The combination of scientific, clinical, and consumer studies on LPLDL, and formulations like the CholBiome product range provide a growing body of evidence for its safe and effective use in reducing biomarkers of cardiovascular risk like total cholesterol, LDL cholesterol, and Apolipoprotein B," said Mikkel Hvid-Hansen, commercial director of probiotics at ProBiotix Health.
"We now have five scientific publications, three human studies, two consumer studies and numerous positive product reviews which gives us confidence in the use of LPLDL.
"We now feel we have evidence broadly comparable to Phase I/II pharmaceutical studies which we can use to open up further partnering or licensing opportunities for use of LPLDL as an OTC [over the counter] product by itself or in combination with existing treatments (e.g. statins), or as a drug biotherapeutic in markets outside the USA."